Company declares cash dividend of $0.05 per share
LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation
and modeling software for pharmaceutical discovery and development,
today announced that its board of directors has declared its next
ongoing quarterly cash dividend of $0.05 per share to its shareholders
will be distributed on Friday, August 10, 2012, for shareholders of
record as of Tuesday, August 7, 2012.
Walt Woltosz, chairman and chief executive officer of Simulations Plus,
said: "As we announced previously, the board of directors decided that
an ongoing quarterly cash dividend is appropriate at this time. This
next dividend distribution will be our third after the initial
distribution in March of this year. As reported in our third quarter
conference call on Thursday, July 12, our cash position is as strong as
it was prior to the last dividend distribution, therefore paying the
dividend has not prevented us from adding cash to our balance sheet."
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug
discovery and development simulation and modeling software, which is
licensed to and used in the conduct of drug research by major
pharmaceutical, biotechnology, agrochemical, and food industry companies
worldwide. The Company also provides a productivity tool called
Abbreviate! for PCs and an educational software series for science
students in middle and high schools known as FutureLab?.
Simulations Plus, Inc., is headquartered in Southern California and
trades on the NASDAQ Capital Market under the symbol "SLP." For more
information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 ? With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like "believe,"
"expect" and "anticipate" mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to
identify and close acquisitions on terms favorable to the Company, and a
sustainable market. Further information on our risk factors is contained
in our quarterly and annual reports as filed with the U.S. Securities
and Exchange Commission.
